SCHEMBL16989282

SCHEMBL16989282

COc1ccc(CNc2nccc(C)c2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 2/20 0.46
F2 P00734 1/20 0.46
NPC1 O15118 1/20 0.46
KDM4E B2RXH2 1/20 0.46
ASPH Q12797 1/20 0.46
KDM8 Q8N371 1/20 0.46
VNN1 O95497 2/20 0.44
CLK4 Q9HAZ1 1/20 0.44
BDKRB1 P46663 2/20 0.43
AURKA O14965 1/20 0.43
RPS6KB1 P23443 1/20 0.43
CDK5 Q00535 2/20 0.43
CDK5R1 Q15078 2/20 0.43
CLK1 P49759 1/20 0.43
MAPT P10636 1/20 0.43
EGFR P00533 1/20 0.43
POLB P06746 1/20 0.43
NR2F2 P24468 1/20 0.43
MAPK14 Q16539 1/20 0.42
ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16991862 0.84 KDM4E (0.56) KLKB1NPC1KDM4EASPHKDM8
SCHEMBL18476454 0.76 CYP2C9 (0.37) ALDH1A1
SCHEMBL16856919 0.75 MAPT (0.52) NPC1KDM4EASPHKDM8VNN1
SCHEMBL31289746 0.73 VNN1 (0.46) KLKB1F2KDM4EASPHKDM8
SCHEMBL31184855 0.72 THRB (0.55) NPC1KDM4EASPHKDM8VNN1
SCHEMBL18088826 0.72 VNN1 (0.45) KLKB1F2NPC1KDM4EASPH
SCHEMBL29142175 0.72 NPC1 (0.47) KLKB1F2NPC1KDM4EASPH
SCHEMBL31289825 0.71 PTK2 (0.43) KLKB1F2KDM4EASPHKDM8
SCHEMBL28283742 0.71 NPC1 (0.64) NPC1CLK4MAPTEGFRPOLB
SCHEMBL31184956 0.70 ATR (0.52) KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214931-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS Cadrenal Therapeutics, Inc. 2025-07-03 US disclosed
US-12084414-B2 Therapeutic compounds and compositions EXITHERA PHARMACEUTICALS, INC. (US) 2024-09-10 US disclosed
EP-4309653-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS Exithera Pharmaceuticals Inc. (US) 2024-01-24 EP disclosed
CN-116444506-A Therapeutic compounds and compositions 艾克赛特赫拉制药有限责任公司 2023-07-18 CN disclosed
EP-3102200-B1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS EXITHERA PHARMACEUTICALS INC (US) 2023-04-05 EP disclosed
CN-108892661-B Therapeutic compounds and compositions 艾克赛特赫拉制药有限责任公司 2023-03-14 CN disclosed
US-20220281813-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS EXITHERA PHARMACEUTICALS, INC. 2022-09-08 US disclosed
US-11198673-B2 Therapeutic compounds and compositions EXITHERA PHARMACEUTICALS, INC. (US) 2021-12-14 US disclosed
US-10259785-B2 Therapeutic compounds and compositions EXITHERA PHARMACEUTICALS, INC. (US) 2019-04-16 US disclosed
CN-108892661-A Therapeutic compounds and composition 艾克赛特赫拉制药有限责任公司 2018-11-27 CN disclosed
US-20180244614-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS EXITHERA PHARMACEUTICALS, INC. 2018-08-30 US disclosed
CN-106029064-B Therapeutic compounds and compositions 艾克赛特赫拉制药有限责任公司 2018-08-14 CN disclosed
US-9994521-B2 Therapeutic compounds and compositions EXITHERA PHARMACEUTICALS, INC. (US) 2018-06-12 US disclosed
US-20170037003-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS Cadrenal Therapeutics, Inc. 2017-02-09 US disclosed
EP-3102200-A2 THERAPEUTIC COMPOUNDS AND COMPOSITIONS Exithera Pharmaceuticals Inc. (US) 2016-12-14 EP disclosed
US-9499532-B2 Therapeutic compounds and compositions eXIthera Pharmaceuticals Inc. (US) 2016-11-22 US disclosed
US-20150225389-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS eXIthera Pharmaceuticals Inc. (US) 2015-08-13 US disclosed
WO-2015120062-A2 THERAPEUTIC COMPOUNDS AND COMPOSITIONS eXIthera Pharmaceuticals Inc. (US) 2015-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170037003-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS KLK5, KLKB1, KLK2 KLKB1 2/4885F2 21/4885NPC1 1058/4885
US-12084414-B2 Therapeutic compounds and compositions KLK5, KLKB1, KLK2 KLKB1 2/4885F2 21/4885NPC1 1058/4885
US-11198673-B2 Therapeutic compounds and compositions KLK5, KLKB1, KLK2 KLKB1 2/4885F2 21/4885NPC1 1058/4885
US-20220281813-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS KLK5, KLKB1, KLK2 KLKB1 2/4885F2 21/4885NPC1 1058/4885
US-10259785-B2 Therapeutic compounds and compositions KLK5, KLKB1, KLK2 KLKB1 2/4885F2 21/4885NPC1 1058/4885
US-20150225389-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS KLK5, KLKB1, KLK2 KLKB1 2/4885F2 21/4885NPC1 1058/4885
US-20250214931-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS KLK5, KLKB1, KLK2 KLKB1 2/4885F2 21/4885NPC1 1058/4885
US-20180244614-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS KLK5, KLKB1, KLK2 KLKB1 2/4885F2 21/4885NPC1 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.